Tumor immunotherapy has become one of the main treatments for tumors. Inhibition of the pathways involving programmed cell death receptor 1 (PD-1) and its ligand (PD-L1) has gained favor in anticancer therapy, and can effectively prolong the survival of patients with cancer; however, numerous patients have PD-1/PD-L1 inhibitor primary resistance. The efficacy of anti-PD-1/PD-L1 therapy is related to the host tumor microenvironment. Radiation therapy can promote the body’s antitumor immunity, change the tumor microenvironment, and synergize with anti-PD-1/PD-L1 treatment. Preclinical and clinical trials have shown that PD-1/PD-L1 inhibitor combined with radiotherapy has a significant effect. We review the synergistic antitumor mechanism and clinical trials of radiotherapy combined with anti-PD-1/PD-L1 therapy.
CalifanoRKerrKMorganRD, et al. Immune checkpoint blockade: a new era for non-small cell lung cancer. Curr Oncol Rep2016; 18: 9.
2.
ConstantinidouAAlifierisCTrafalisDT.Targeting programmed cell death-1 (PD-1) and ligand (PD-L1): a new era in cancer active immunotherapy. Pharmacol Ther2019; 194: 84–106.
3.
IwaiYHamanishiJChamotoK, et al. Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci2017; 24: 26.
4.
LiYLiuJGaoL, et al. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance. Immunol Lett2020; 220: 88–96.
5.
JiangWChanCKWeissmanIL, et al. Immune priming of the tumor microenvironment by radiation. Trends Cancer2016; 2: 638–645.
6.
ArnoldKMFlynnNJRabenA, et al. The impact of radiation on the tumor microenvironment: effect of dose and fractionation schedules. Cancer Growth Metastasis2018; 11: 1179064418761639.
7.
SorensenPKussmannMRosenA, et al. Identification of protein-protein interfaces implicated in CD80-CD28 costimulatory signaling. J Immunol2004; 172: 6803–6809.
8.
ChenLPFliesDB.Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol2013; 13: 227–242.
9.
WuXZhangHXingQ, et al. PD-1(+) CD8(+) T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients. Br J Cancer2014; 111: 1391–1399.
10.
GongJChehrazi-RaffleAReddiS, et al. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer2018; 6: 18.
11.
JiangQXieMHeM, et al. Anti-PD-1/PD-L1 antibodies versus docetaxel in patients with previously treated non-small-cell lung cancer. Oncotarget2018; 9: 7672–7683.
12.
RobertCSchachterJLongGV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med2015; 372: 2521–2532.
13.
TaubeJMKleinABrahmerJR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res2014; 20: 5064–5074.
14.
CarbogninLPilottoSMilellaM, et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PloS One2015; 10: e0130142.
15.
TangHLiangYAndersRA, et al. PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. J Clin Invest2018; 128: 580–588.
16.
PowlesTEderJPFineGD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature2014; 515: 558–562.
17.
YarchoanMJohnsonBALutzER, et al. Targeting neoantigens to augment antitumour immunity [correction 2017; 17: 209]. Nat Rev Cancer2017; 17: 1.
18.
GubinMMZhangXSchusterH, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature2014; 515: 577–581.
19.
McGranahanNFurnessAJSRosenthalR, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science2016; 351: 1463–1469.
20.
GreillierLTomasiniPBarlesiF.The clinical utility of tumor mutational burden in non-small cell lung cancer. Transl lung Cancer Res2018; 7: 639–646.
21.
IshikawaTFujitaTSuzukiY, et al. Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability. Cancer Res2003; 63: 5564–5572.
22.
ChaeYKAnkerJFBaisP, et al. Mutations in DNA repair genes are associated with increased neo-antigen load and activated T cell infiltration in lung adenocarcinoma. Oncotarget2018; 9: 7949–7960.
23.
RizviHSanchez-VegaFLaK, et al. Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol2018; 36: 633–641.
24.
AsaokaYIjichiHKoikeK.PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med2015; 373: 1979.
25.
JohnsonDBEstradaMVSalgadoR, et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun2016; 7: 10.
26.
RoemerMGMReddRACaderFZ, et al. Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma. J Clin Oncol2018; 36: 942–950.
27.
ChowellDMorrisLGTGriggCM, et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science2018; 359: 582–587.
28.
Dieu-NosjeanM-CAntoineMDanelC, et al. Long-term survival for patients with non–small-cell lung cancer with intratumoral lymphoid structures. 2008; 26: 4410–4417.
29.
GiraldoNABechtEPagèsF, et al. Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. 2015; 21: 3031–3040.
30.
YaoSWangSDZhuYW, et al. PD-1 on dendritic cells impedes innate immunity against bacterial infection. Blood2009; 113: 5811–5818.
31.
GarrisCSArlauckasSPKohlerRH, et al. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFNγ and IL-12. Immunity2018; 49: 1148–1161.
32.
ChenDSMellmanI.Elements of cancer immunity and the cancer-immune set point. Nature2017; 541: 321–330.
33.
TaltsJFWirlGDictorM, et al. Tenascin-C modulates tumor stroma and monocyte macrophage recruitment but not tumor growth or metastasis in a mouse strain with spontaneous mammary cancer. J Cell Sci1999; 112: 1855–1864.
34.
ValkenburgKCde GrootAEPientaKJ.Targeting the tumour stroma to improve cancer therapy. Nat Rev Clin Oncol2018; 15: 366–381.
35.
SimoniYBechtEFehlingsM, et al. Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature2018; 557: 575–579.
36.
ScheperWKeldermanSFanchiLF, et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nat Med2019; 25: 89–94.
37.
DemariaSNgBDevittML, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys2004; 58: 862–870.
38.
DuPageMMazumdarCSchmidtLM, et al. Expression of tumour-specific antigens underlies cancer immunoediting. Nature2012; 482: 405–409.
39.
HodgeJWSharpHJGameiroSR.Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation. Cancer Biother Radiopharm2012; 27: 12–22.
40.
SchumacherTNSchreiberRD.Neoantigens in cancer immunotherapy. Science2015; 348: 69–74.
41.
SethuramanSNRanjanA.Neoantigen activation, protein translocation and targeted drug delivery in combination with radiotherapy. Ther Deliv2016; 7: 377–385.
42.
FormentiSCDemariaS.Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst2013; 105: 256–265.
43.
MessmerDYangHTelusmaG, et al. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol2004; 173: 307–313.
44.
ObeidMTesniereAGhiringhelliF, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med2007; 13: 54–61.
45.
AymericLApetohLGhiringhelliF, et al. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res2010; 70: 855–858.
46.
ReitsEAHodgeJWHerbertsCA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med2006; 203: 1259–1271.
47.
Chiriva-InternatiMGrizziFPinkstonJ, et al. Gamma-radiation upregulates MHC class I/II and ICAM-I molecules in multiple myeloma cell lines and primary tumors. In Vitro Cell Dev Biol Anim2006; 42: 89–95.
48.
HallahanDESpriggsDRBeckettMA, et al. Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation. Proc Natl Acad Sci USA1989; 86: 10104–10107.
49.
LugadeAASorensenEWGerberSA, et al. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol2008; 180: 3132–3139.
50.
MatsumuraSWangBMKawashimaN, et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol2008; 181: 3099–3107.
51.
DuJSuSLiHY, et al. Low dose irradiation increases adoptive cytotoxic T lymphocyte migration in gastric cancer. Exp Ther Med2017; 14: 5711–5716.
52.
DengLLiangHBurnetteB, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest2014; 124: 687–695.
53.
ParkSSDongHLiuX, et al. PD-1 Restrains radiotherapy-induced abscopal effect. Cancer Immunol Res2015; 3: 610–619.
54.
AntoniaSJVillegasADanielD, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med2017; 377: 1919–1929.
55.
TheelenWPeulenHMULalezariF, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol2019; 5: 1276–1282.
56.
YamaguchiOKairaKHashimotoK, et al. Radiotherapy is an independent prognostic marker of favorable prognosis in non-small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab. Thorac Cancer2019; 10: 992–1000.
57.
MaityAMickRHuangAC, et al. A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours. Br J Cancer2018; 119: 1200–1207.
58.
HuangACPostowMAOrlowskiRJ, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature2017; 545: 60–65.
59.
WangPFengY.A mathematical model of tumor volume changes during radiotherapy. Sci World J2013; 2013: 181070.
60.
FerraraRMezquitaLTexierM, et al. Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol2018; 4: 1543–1552.
61.
CakirMOKircaOGunduzS, et al. Hyperprogression after immunotherapy: a comprehensive review. J Buon2019; 24: 2232–2241.
62.
WangXPWangFZhongMJ, et al. The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy. Mol Cancer2020; 19: 15.
63.
KimJYLeeKHKangJ, et al. Hyperprogressive disease during anti-PD-1 (PDCD1)/PD-L1 (CD274) therapy: a systematic review and meta-analysis. Cancers2019; 11: 18.
64.
ChampiatSDercleLAmmariS, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res2017; 23: 1920–1928.
65.
WangPFChenYSongSY, et al. Immune-related adverse events associated with anti-PD-1/PD-L1 treatment for malignancies: a meta-analysis. Frontiers Pharmacol2017; 8: 730.
66.
WangFLuoYTianX, et al. Impact of radiotherapy concurrent with anti-PD-1 therapy on the lung tissue of tumor-bearing mice. Radiat Res2019; 191: 271–277.
67.
DuSZhouLAlexanderGS, et al. PD-1 Modulates radiation-induced cardiac toxicity through cytotoxic T lymphocytes. J Thorac Oncol2018; 13: 510–520.
68.
ShaverdianNLisbergAEBornazyanK, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol2017; 18: 895–903.
69.
AndersonESPostowMAWolchokJD, et al. Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment. J Immunother Cancer2017; 5: 76.
70.
LinikerEMenziesAMKongBY, et al. Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. Oncoimmunology2016; 5: e1214788.
71.
LesueurPEscandeAThariatJ, et al. Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: a multicentric retrospective study from the GFPC. Cancer Med2018; 7: 5505–5513.
72.
TreeACJonesKHafeezS, et al. Dose-limiting urinary toxicity with pembrolizumab combined with weekly hypofractionated radiation therapy in bladder cancer. Int J Radiat Oncol Biol Phys2018; 101: 1168–1171.
73.
DovediSJAdlardALLipowska-BhallaG, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res2014; 74: 5458–5468.
74.
KooTKimIA.Radiotherapy and immune checkpoint blockades: a snapshot in 2016. Radiat Oncol J2016; 34: 250–259.
75.
QianJMYuJBKlugerHM, et al. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer2016; 122: 3051–3058.
76.
KotechaRKimJMMillerJA, et al. The impact of sequencing PD-1/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis. Neuro-Oncology2019; 21: 1060–1068.
77.
ChenLDDouglassJKleinbergL, et al. Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma. Int J Radiat Oncol Biol Phys2018; 100: 916–925.
78.
MurphyBWalkerJBassaleS, et al. Concurrent radiosurgery and immune checkpoint inhibition improving regional intracranial control for patients with metastatic melanoma. Am J Clin Oncol Cancer Clin Trials2019; 42: 253–257.
79.
AhmedKAKimSArringtonJ, et al. Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases. J Neuro-Oncol2017; 133: 331–338.
80.
BernsteinMBKrishnanSHodgeJW, et al. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?Nat Rev Clin Oncol2016; 13: 516–524.
81.
GrecoCParesOPimentelN, et al. Spinal metastases: from conventional fractionated radiotherapy to single-dose SBRT. Rep Pract Oncol Radiother2015; 20: 454–463.
82.
LeeYAuhSLWangY, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood2009; 114: 589–595.
83.
FormentiSCDemariaS.Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst2013; 105: 256–265.
84.
Vanpouille-BoxCAlardAAryankalayilMJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun2017; 8: 15.
85.
DewanMZGallowayAEKawashimaN, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res2009; 15: 5379–5388.
86.
XuJEscamillaJMokS, et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res2013; 73: 2782–2794.
87.
BanerjeeAChabriaYRajesh KannaNR, et al. Role of tumor specific niche in colon cancer progression and emerging therapies by targeting tumor microenvironment. Adv Exp Med Biol Epub 2019 Apr 11.
88.
CassettaLPollardJW.Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov2018; 17: 887–904.
89.
SchaueDRatikanJAIwamotoKS, et al. Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys2012; 83: 1306–1310.
90.
PrakashHKlugFNadellaV, et al. Low doses of gamma irradiation potentially modifies immunosuppressive tumor microenvironment by retuning tumor-associated macrophages: lesson from insulinoma. Carcinogenesis2016; 37: 301–313.
91.
ChooYWKangMKimHY, et al. M1 macrophage-derived nanovesicles potentiate the anticancer efficacy of immune checkpoint inhibitors. ACS Nano2018; 12: 8977–8993.
92.
MarciscanoAEGhasemzadehANirschlTR, et al. Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy. Clin Cancer Res2018; 24: 5058–5071.
